Human medicines European public assessment report (EPAR): Alli (previously Orlistat GSK), orlistat, Date of authorisation: 22/07/2007, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Vantavo (previously Alendronate sodium and colecalciferol, MSD), alendronic acid,colecalciferol, Date of authorisation: 16/10/2009, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Adrovance, alendronic acid,colecalciferol, Date of authorisation: 04/01/2007, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Esperoct, turoctocog alfa pegol, Date of authorisation: 20/06/2019, Revision: 8, Status: Authorised

Clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg) - Scientific guideline

EMA workshop on the challenges in drug development, regulation and clinical practice in hemoglobinopathies, Online, European Medicines Agency, Amsterdam, the Netherlands, from 1 July 2024, 14:00 (CEST) to 1 July 2024, 18:00 (CEST)

European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties meeting with all eligible organisations - 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, 20 November 2024

Human medicines European public assessment report (EPAR): Supemtek, Quadrivalent influenza vaccine (recombinant, prepared in cell culture), Date of authorisation: 16/11/2020, Revision: 6, Status: Authorised

Guidance for applicants seeking scientific support and advice on traditional herbal medicinal products

Human medicines European public assessment report (EPAR): Arsenic trioxide Accord, arsenic trioxide, Date of authorisation: 14/11/2019, Revision: 7, Status: Authorised